Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kezar Life Sciences (KZR) Enterprise Value (2021 - 2026)

Kezar Life Sciences (KZR) has disclosed Enterprise Value for 5 consecutive years, with -$71.9 million as the latest value for Q4 2025.

  • For Q4 2025, Enterprise Value rose 45.65% year-over-year to -$71.9 million; the TTM value through Dec 2025 reached -$71.9 million, up 45.65%, while the annual FY2025 figure was -$71.9 million, 45.65% up from the prior year.
  • Enterprise Value hit -$71.9 million in Q4 2025 for Kezar Life Sciences, up from -$90.2 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$71.9 million in Q4 2025 and bottomed at -$306.8 million in Q2 2022.
  • Average Enterprise Value over 5 years is -$181.6 million, with a median of -$172.0 million recorded in 2024.
  • Year-over-year, Enterprise Value tumbled 140.46% in 2022 and then soared 45.65% in 2025.
  • Kezar Life Sciences' Enterprise Value stood at -$208.4 million in 2021, then crashed by 32.74% to -$276.6 million in 2022, then grew by 27.19% to -$201.4 million in 2023, then surged by 34.33% to -$132.2 million in 2024, then skyrocketed by 45.65% to -$71.9 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$71.9 million, -$90.2 million, and -$100.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.